UNHUnitedHealth
$403.17-0.48%Delayed market dataHealth insuranceHealthcare services & payers · 7 peers →Key levels and trade conditions
Delayed quotes · Technical conditionsShowing the near-term range, based on the latest 5 completed sessions and updated after each close.
Hold and monitor; no addition yet
Signals require closing-price and volume confirmation; review the company research below before acting.
When does defense take priority?
Close beyond this level with session volume ≥ 1.5× the previous 20 completed sessions’ average.
Confirmed close below $388.00 → consider reducing
When to consider adding?
Close beyond this level with session volume ≥ 1.5× the previous 20 completed sessions’ average.
Confirmed close above $406.72 → consider a staged addition
01Newstock overall assessment
The conclusion first, followed by the evidence that matters most.
Watch — await combined confirmation. An entry assessment has not yet been established.
02What happened recently
Company events, industry developments and market conditions — facts separated from possible explanations.
US 10Y yield 5.14%2026-11-13T18:40:14.000Z
VIX 19.472026-11-13T18:40:16.000Z
Dollar index 103.382026-11-13T18:45:17.000Z
Market and sector reference
UNH -0.47% · SPY -0.49% · Peer average -0.59% (CI, CVS, ELV, HCA, HUM, MCK)
2026-11-13T18:57:59.000Z · Yahoo · Aligned-session reference, not a causal attribution.
Related news and impact paths
Recent news related to this stock
0 direct · 2 2nd-order · 0 thematicRanked by model assessment and recency. Labels use the original model impact, not expected returns. Impact percentages are model estimates, not observed price changes, probabilities or guaranteed returns.
- #1Impact1.4%Favorable2nd-orderMicrosoft develops AI tool that can diagnose 'sequentially' like a doctor22d ago
If insurers and care delivery systems adopt AI-assisted diagnosis, claims review and triage efficiency could improve, lowering some operating costs.
Also named: MSFT · GOOGL · AMZN · ORCL · NOW · HCA
- #2Impact0.8%Adverse2nd-orderMicrosoft's Mustafa Suleyman says its AI outperforms doctors on hard cases as he chases ‘medical superintelligence'22d ago
Better diagnostic consistency from AI could prompt redesigns of utilization management and triage workflows, creating near-term cost-optimization pressure rather than direct revenue upside.
Also named: MSFT · AMZN · VEEV · ORCL · GEHC · HCA
03Is the company worth considering?
Business quality, financials, valuation and analyst disagreements.
🏛️ Company factsSEC filings + FINRA official data
Annual revenue $447.6B · latest quarter down 0.4% YoY · reported FY net income of $12.1B · short-sale volume share below its recent available-day average.
FY revenue
$447.6B
2025-12
Latest Q YoY
-0.4%
FY net income
$12.1B
Diluted EPS
$13.28
Short-sale volume share
32.4%
2026-11-05 · Recent available-day avg 43.1% · below recent average
Short-sale volume as a share of trades covered by the FINRA file, not all market trading or outstanding short positions. Changes do not establish that short sellers are adding or covering positions.
🐋 Ownership filings (last 180 days)
Recent 13D/13G beneficial ownership filings, which may include amendments. A filing does not establish a recent purchase or a current holding, and its form type alone does not establish investment intent. Read the original filing for details.
- 2026-08-07SCHEDULE 13GSTATE STREET CORP
Historical results versus analyst expectations
🎯 Market expectations
Estimate context score High · 73/100Nasdaq analyst consensus · currently available data
- Sep 2026$4.69 vs $4.12+13.83%
- Jun 2026$6.38 vs $4.94+29.15%
- Mar 2026$7.23 vs $6.46+11.92%
- Dec 2025$2.11 vs $2.09+0.96%
The takeaway
EPS exceeded the corresponding consensus estimates by an average of 14% in the quarters shown. This is not a hurdle for the next report or a forecast of the stock's reaction. Analysts made 3 upward revisions over the past four weeks. Analysts made 3 downward revisions over the past four weeks.
Analyst estimates, not our forecast · not investment advice
Analyst consensus and disagreement
Target-price summary $402.00–$531.00 · Consensus $482.69
Buy / hold / sell 14 / 3 / 0
Nasdaq · Retrieved 2026-11-13T18:59:11.202Z · The aggregate does not provide individual report dates or original theses. It does not establish undervaluation; no analyst rationale is inferred. Targets are not guaranteed outcomes.
Next-quarter EPS estimate (Dec 2026) $2.28 · $2.19–$2.54 · 10 analysts
Four-week estimate revisions: up / down 3 / 3
Estimate dispersion 15.4%
Nasdaq EPS forecasts · retrieved 2026-11-13T18:59:09.113Z04Is now a good time?
Trend, moving averages, volume and key price levels — not the decline alone.
Technical structure · Mixed structure
MA5 $400.99
MA10 $402.19
MA20 $407.43
MA60 $391.83
Last completed-session close $405.13 (+0.54%) · Volume / prior 20-session average 0.72×
Prior 20-session range $388.00–$426.55 · MA20 change over five sessions +0.83% · CMF20 0.08
- Tight-range consolidation
Confirmation to watch: a close above $426.55 with volume at least 1.5× the prior 20-session average. A heavy-volume break below $388.00 weakens the setup.
Completed daily candles only. Daily OHLCV cannot establish accumulation, shakeout or manipulation intent; CMF is a price/volume proxy, not actual fund flows. Thresholds are research rules, not validated success probabilities. Yahoo · 2026-11-12
Price and news
Historical prices and volume. Drag to pan; scroll to zoom.
Related news
05What would change our assessment?
Conditions for reconsidering entry and developments that invalidate the thesis.
Complete the company and technical cross-check before defining entry and invalidation conditions.
Additional risk evidence and model detail
Market View
Crowding
Risk temperature
Tail risk
Triggers
Price and volume
Insider signals
See every affected stock, second-order impact and risk factor. Try Pro free for 7 days — no credit card required.
Start my free trial